Sean P. Nolan - Dec 14, 2023 Form 4 Insider Report for Taysha Gene Therapies, Inc. (TSHA)

Signature
/s/ Kamran Alam, Attorney-in-Fact
Stock symbol
TSHA
Transactions as of
Dec 14, 2023
Transactions value $
$0
Form type
4
Date filed
12/18/2023, 04:46 PM
Previous filing
Aug 16, 2023
Next filing
Jan 4, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TSHA Employee Stock Option (right to buy) Award $0 +467K $0.00 467K Dec 14, 2023 Common Stock 467K $0.70 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The compensation committee of the board of directors of the Issuer certified achievement of certain performance criteria such that 70% of the option shares subject to the performance-based stock option award were earned. The shares underlying the earned potion of the option shall vest and become exercisable in three equal annual installments commencing on December 31, 2024, subject to the Reporting Person's continuous service through each applicable vesting date.